Roche's Cancer Drug Setback: Stocks Tumble
Roche's shares fell over 5% due to the failure of their breast cancer drug candidate, giredestrant, to deliver promising results in a late-stage trial. The trial did not show improved disease progression when combined with Ibrance. The setback challenges the optimistic outlook around the treatment.
Roche's stocks took a hit on Monday, dropping over 5%, as their breast cancer drug candidate, giredestrant, did not meet expectations in its recent trial.
The stock saw a modest recovery during the morning, trading down 4.6% to 325.80 Swiss francs, marking a two-month low. The late-stage trial failed to demonstrate that giredestrant, in combination with Pfizer's Ibrance, was more effective than standard hormonal therapies.
Despite the setback, analysts perceive potential. Barclays' James Gordon suggests the share drop presents a buying opportunity, with market opportunities for add-on treatments not fully realized. However, Jefferies analyst Michael Leuchten anticipates the news will reverse previous positive momentum.
ALSO READ
-
Roche Stock Falls as Breast Cancer Drug Fails Trial Goals
-
Roche's Setback: Giredestrant Fails in Key Breast Cancer Trial
-
Zealand Pharma's Weight-Loss Drug Falls Short, Shares Plummet
-
Zealand Pharma's Shares Plummet After Disappointing Drug Trial Results
-
China, HK shares set for weekly losses on geopolitics, muted policy signals
Google News